Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gasparella, P; Haxhija, EQ; Andersen, R; Barea, M; Baselga, E; Serrano, MB; Berger, S; Bisdorff, AA; Boccara, O; Borgards, P; Bom-Sucesso, M; Boon, LM; Cimpean, AM; Diociaiuti, A; Dvorakova, V; Hachem, ME; Frisk, S; Ghaffarpour, N; Holm, A; Irvine, AD; Kaltoft, M; Kapp, FG; Koskova, O; Kyrklund, K; Madureira, M; Palionis, D; Przewratil, P; Schönewolf-Greulich, B; Stanciulescu, MC; Štěrba, J; Tolonen, J; Vaisnyte, B; van, der, Vleuten, C; Wyrzykowski, D; Kool, LS; Vikkula, M.
The VASCERN-VASCA diagnostic and management pathways for kaposiform hemangioendothelioma.
Eur J Pediatr. 2025; 185(1):14
Doi: 10.1007/s00431-025-06631-6
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Gasparella Paolo
- Haxhija Emir
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- UNLABELLED: The European Reference Network (ERN) on Rare Multisystemic Vascular Diseases (VASCERN) is dedicated to gathering the best expertise in Europe in order to improve and provide high-level healthcare to all patients with rare vascular diseases and provide accessible cross-border healthcare to patients with rare vascular diseases. Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour with local aggressiveness, often associated with a life-threatening coagulopathy known as the Kasabach-Merritt phenomenon (KMP). The Vascular Anomalies Working Group (VASCA-WG) developed diagnostic and therapeutic pathways for the management of KHE using the nominal group technique (NGT), a well-established, structured, multi-stage, facilitated group meeting technique used to generate consensus statements. The pathways were developed following two face-to-face meetings and several web meetings to facilitate discussion. CONCLUSION: VASCA has produced this expert opinion, which reflects the strategies developed by experts and patient representatives on how to approach patients with Kaposiform Hemangiothelioma in a practical manner; here, we present an algorithmic flow chart of this work. WHAT IS KNOWN: • Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular tumor, often associated with a life threatening coagulopathy, and can be challenging to manage. WHAT IS NEW: • The diagnostic and therapeutic pathway for KHE, developed by a multidisciplinary group of experts (VASCA-VASCERN Group), offers concrete offers concrete help in making decisions about managing this condition.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Kasabach-Merritt Syndrome - diagnosis, therapy
- Sarcoma, Kaposi - diagnosis, therapy
- Hemangioendothelioma - diagnosis, therapy
- Critical Pathways - administration & dosage
- Algorithms - administration & dosage
- Europe - administration & dosage
- Child - administration & dosage